Ascent Advisors LLC Makes New Investment in VanEck Biotech ETF $BBH

Ascent Advisors LLC acquired a new stake in VanEck Biotech ETF (NASDAQ:BBH) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 59,450 shares of the company’s stock, valued at approximately $11,178,000. VanEck Biotech ETF makes up approximately 17.7% of Ascent Advisors LLC’s portfolio, making the stock its biggest position. Ascent Advisors LLC owned 3.02% of VanEck Biotech ETF at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC boosted its stake in shares of VanEck Biotech ETF by 3.4% in the first quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock valued at $572,000 after purchasing an additional 100 shares during the period. Wealthfront Advisers LLC increased its stake in VanEck Biotech ETF by 2.3% during the 4th quarter. Wealthfront Advisers LLC now owns 5,513 shares of the company’s stock worth $1,043,000 after buying an additional 122 shares during the period. Evelyn Partners Asset Management Ltd increased its stake in VanEck Biotech ETF by 16.9% during the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock worth $178,000 after buying an additional 136 shares during the period. Empowered Funds LLC acquired a new position in VanEck Biotech ETF in the 4th quarter worth $38,000. Finally, Stifel Financial Corp lifted its holdings in VanEck Biotech ETF by 3.3% in the 4th quarter. Stifel Financial Corp now owns 6,848 shares of the company’s stock worth $1,296,000 after buying an additional 219 shares in the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Price Performance

NASDAQ:BBH opened at $209.28 on Thursday. The firm has a 50-day moving average of $190.26 and a two-hundred day moving average of $191.32. VanEck Biotech ETF has a 1-year low of $154.75 and a 1-year high of $212.54.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.